Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study
- PMID: 19280229
- DOI: 10.1007/s00467-009-1138-5
Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study
Abstract
Long-term outcome of idiopathic steroid-resistant nephrotic syndrome was retrospectively studied in 78 children in eight centers for the past 20 years. Median age at onset was 4.4 years (1.1-15.0 years) and the gender ratio was 1.4. Median follow-up period was 7.7 years (1.0-19.7 years). The disease in 45 patients (58%) was initially not steroid-responsive and in 33 (42%) it was later non-responsive. The main therapeutic strategies included administration of ciclosporine (CsA) alone (n = 29; 37%) and CsA + mycophenolate mofetil (n = 18; 23%). Actuarial patient survival rate after 15 years was 97%. Renal survival rate after 5 years, 10 years and 15 years was 75%, 58% and 53%, respectively. An age at onset of nephrotic syndrome (NS) > 10 years was the only independent predictor of end-stage renal disease (ESRD) in a multivariate analysis using a Cox regression model (P < 0.001). Twenty patients (26%) received transplants; ten showed recurrence of the NS: seven within 2 days, one within 2 weeks, and two within 3-5 months. Seven patients lost their grafts, four from recurrence. Owing to better management, kidney survival in idiopathic steroid-resistant nephrotic syndrome (SRNS) has improved during the past 20 years. Further prospective controlled trials will delineate the potential benefit of new immunosuppressive treatment.
Similar articles
-
Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.Pediatr Nephrol. 2005 Jul;20(7):914-9. doi: 10.1007/s00467-005-1877-x. Epub 2005 May 13. Pediatr Nephrol. 2005. PMID: 15891923 Clinical Trial.
-
[Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].Przegl Lek. 2006;63 Suppl 3:44-8. Przegl Lek. 2006. PMID: 16898486 Clinical Trial. Polish.
-
Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study.Clin Ther. 2004 Sep;26(9):1411-8. doi: 10.1016/j.clinthera.2004.09.012. Clin Ther. 2004. PMID: 15531003 Clinical Trial.
-
New treatment strategies in idiopathic nephrotic syndrome.Minerva Pediatr. 2012 Apr;64(2):135-43. Minerva Pediatr. 2012. PMID: 22495188 Review.
-
[Efficacy and safety of cyclosporine A in treatment of refractory nephrotic syndrome in children: a systematic review of randomized controlled trials].Zhonghua Er Ke Za Zhi. 2009 Dec;47(12):898-903. Zhonghua Er Ke Za Zhi. 2009. PMID: 20193140 Chinese.
Cited by
-
Identification of novel mutations and phenotype in the steroid resistant nephrotic syndrome gene NUP93: a case report.BMC Nephrol. 2019 Jul 17;20(1):271. doi: 10.1186/s12882-019-1458-z. BMC Nephrol. 2019. PMID: 31315584 Free PMC article.
-
Long-Term Outcome of Secondary Steroid-Resistant Nephrotic Syndrome in Chinese Children.Kidney Int Rep. 2021 May 12;6(8):2144-2150. doi: 10.1016/j.ekir.2021.05.001. eCollection 2021 Aug. Kidney Int Rep. 2021. PMID: 34386663 Free PMC article.
-
Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries.Eur J Pediatr. 2017 May;176(5):647-654. doi: 10.1007/s00431-017-2891-2. Epub 2017 Mar 16. Eur J Pediatr. 2017. PMID: 28303389
-
Long-term results of children diagnosed with idiopathic nephrotic syndrome; single center experience.Turk Pediatri Ars. 2015 Mar 1;50(1):37-44. doi: 10.5152/tpa.2015.2086. eCollection 2015 Mar. Turk Pediatri Ars. 2015. PMID: 26078695 Free PMC article.
-
Cyclophosphamide versus cyclosporine A therapy in steroid-resistant nephrotic syndrome: a retrospective study with a mean 5-year follow-up.J Int Med Res. 2018 Nov;46(11):4506-4517. doi: 10.1177/0300060518782017. Epub 2018 Sep 5. J Int Med Res. 2018. PMID: 30185089 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous